Prognostic value of NOB1 expression levels in various cancers: a systematic review and meta-analysis

Abstract

Aim: This study evaluates the prognostic significance of NOB1 expression levels in various cancers. Patients & methods: Studies examining NOB1 expression in cancer, encompassing data from 1694 patients across 14 studies, were analyzed for overall survival (OS) and progression-free survival (PFS) using hazard ratios (HRs) and 95% CIs, and for clinicopathological parameters using relative risks (RRs). Results: High NOB1 expression correlated with shorter OS (HR: 2.12, 95% CI: 1.82–2.48) and PFS (HR: 2.23, 95% CI: 1.62–3.07) and was associated with adverse tumor characteristics such as stage and metastasis. Conclusion: Elevated NOB1 expression in various tumors signifies a poor prognosis, serving as a predictive marker for malignancy outcomes.

PROSPERO Register Number: CRD42023394051

Plain language summary

This study looked at how a protein called NOB1 affects cancer. NOB1 is usually found in healthy parts of the body like the lungs and liver, but it might also show up in cancer. We checked data from many sources to see if there's a connection between NOB1 and cancer's severity. After studying 1694 samples from 14 studies, we found that people with more NOB1 in their bodies had a tougher time with cancer. Their disease got worse quicker and they did not live as long as those with less NOB1. Also, higher NOB1 levels were linked to more serious and aggressive cancers. This means that NOB1 could help doctors predict how bad a patient's cancer is and plan treatments better.

TWEETABLE ABSTRACT

A comprehensive meta-analysis indicates that elevated NOB1 expression is associated with shorter survival in various cancers. This discovery underscores the potential of NOB1 as a prognostic marker in malignant tumors. #CancerResearch #PrognosticMarker

Article highlights

• Cancer is a significant global health concern, leading to high mortality rates worldwide.

• Timely diagnosis, treatment and prognostic assessment of cancer patients remain challenging.

• The search for biological markers related to cancer occurrence, progression and prognosis is crucial.

• NOB1 gene, associated with cell cycle regulation and protein expression, has garnered attention for its potential role in cancer.

Methods

• A systematic literature search was conducted following PRISMA-P guidelines.

• Inclusion criteria involved cohort or case-control studies with confirmed malignancy diagnosis and available survival data.

• Data extraction and quality assessment were performed independently by two researchers.

• Statistical analyses were conducted using STATA software, focusing on HRs and RRs to evaluate NOB1's prognostic value and clinicopathological associations.

Results

• Literature screening yielded 14 eligible studies from China, covering nine cancer types and involving 1694 cases.

• Higher NOB1 expression levels were significantly associated with shorter OS and PFS in cancer patients.

• NOB1 expression correlated with tumor stage, degree of differentiation, lymph node metastasis and distant metastasis.

• Subgroup analyses showed consistent associations across different cancer types and sample sizes.

Discussion

• NOB1's aberrant expression in various cancers suggests its potential as a prognostic marker and therapeutic target.

• The exact molecular mechanisms underlying NOB1's role in tumorigenesis and progression remain unclear.

• Future research should address the limitations of existing studies and explore NOB1's prognostic value across a broader range of cancers.

Conclusion

• High NOB1 expression is associated with poor prognosis in various cancers, indicating its potential as a prognostic marker.

• NOB1 expression levels may help stratify patients for risk assessment and treatment planning.

• Further validation through larger, multicenter studies and standardized clinical trials is warranted to confirm NOB1's prognostic significance across different cancer types.

Keywords: :

• meta-analysis
• nin one binding protein 1
• NOB1
• prognosis
• tumor

Supplemental material

Supplementary data for this article can be accessed at https://doi.org/10.1080/17520363.2024.2352408

Author contributions

Conceptualization, B Zou, Y Xu; writing-original draft preparation, Y Zhang, Z Li; writing-review and editing, Y Zhang, Z Li, X Chen and Y Huang; supervision, B Zou, Y Xu; funding acquisition, B Zou, Y Xu. All authors have read and agreed to the published version of the manuscript.

Financial disclosure

This research was funded by the Clinical Research Incubation Project, West China Hospital, Sichuan University (grant no. 2021HXFH022); the Science and Technology Department of Sichuan Province (grant no. 22GJHZ0015); and the Beijing Medical Award Foundation (grant no. YXJL-2021-1009-0660). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

Medical writing support was provided by Cambridge Proofreading LLC and was funded by Clinical Research Incubation Project, West China Hospital, Sichuan University.

Additional information

Funding

This research was funded by the Clinical Research Incubation Project, West China Hospital, Sichuan University (grant no. 2021HXFH022); the Science and Technology Department of Sichuan Province (grant no. 22GJHZ0015); and the Beijing Medical Award Foundation (grant no. YXJL-2021-1009-0660).